Replies to post #225979 on Biotech Values

[DewDiligence]

OXUR.BR -43% on phase-2 failure in DME:

https://finance.yahoo.com/news/oxurion-announces-top-line-results-063000823.html

The Part A data showed THR-687 to be safe and well tolerated with no serious adverse events and none of the patients required rescue medication through Month 3, however, there was insufficient evidence of efficacy on the key endpoints (Best-Corrected Visual Acuity and Central Subfield Thickness). As a result, Oxurion has decided not to advance THR-687 to Part B of the INTEGRAL trial.

In other words, the DME program is kaput. A prior phase-2 trial in the same indication failed in 2019 (#msg-150629948).